NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free EDGE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.56▼$4.3650-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume1.82 million shsAverage Volume373,201 shsMarket Capitalization$126.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Edge Therapeutics alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Edge Therapeutics Stock (NASDAQ:EDGE)PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. EDGE Stock News HeadlinesMay 7, 2024 | finance.yahoo.comTopas Therapeutics Appoints Hugo Fry as CEOMay 7, 2024 | markets.businessinsider.comAtopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business UpdateMay 8, 2024 | Behind the Markets (Ad)BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.May 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy DataMay 2, 2024 | uk.finance.yahoo.comCorcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...May 2, 2024 | finanznachrichten.de500Newswire, LLC: CB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comCB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comKelonia Therapeutics to Participate in Upcoming Scientific ConferencesMay 8, 2024 | Behind the Markets (Ad)BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.April 30, 2024 | finance.yahoo.comAsimov Achieves 10x Improvement in Lentiviral Production, Launches New Stable Cell Line Development ServiceApril 29, 2024 | finanznachrichten.deEVOX THERAPEUTICS LIMITED: Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerApril 29, 2024 | markets.businessinsider.comEvox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerApril 26, 2024 | finance.yahoo.comRactigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBCApril 26, 2024 | msn.comMundipharma to acquire rezafungin assets from Cidara TherapeuticsApril 26, 2024 | msn.comFDA approves Utility Therapeutics’ Pivya tablets for UTIsApril 25, 2024 | finance.yahoo.comBiologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033April 24, 2024 | markets.businessinsider.comCutting-edge RM6 Million Laboratory Opens at UMMC to Advance Cancer TreatmentApril 23, 2024 | finance.yahoo.comRed Arrow Therapeutics Inc. closes $4.5M Seed Extension roundApril 22, 2024 | uk.finance.yahoo.comVect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and TumorsApril 22, 2024 | markets.businessinsider.comIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesApril 19, 2024 | finance.yahoo.comPeptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearchApril 18, 2024 | markets.businessinsider.comMaintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy ResultsApril 18, 2024 | finance.yahoo.comPanasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing TechnologyApril 15, 2024 | finance.yahoo.comMyeloid Therapeutics to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 15, 2024 | finance.yahoo.comGastrointestinal Therapeutics and Diagnostics: Propelling Global Markets with Cutting-Edge Technologies by BCC Research LLCApril 14, 2024 | msn.comHow cutting-edge therapies—like Ozempic—are changing the drug-pricing landscapeApril 11, 2024 | msn.comPrelude Therapeutics Unveils Promising Cancer Treatment Advances at AACR MeetingSee More Headlines Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today5/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book3.97Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$118.95 million OptionableNot Optionable Beta3.65 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesFrank K. Bedu-AddoPresident, Chief Executive Officer & DirectorMichael P. KingChief Financial OfficerLauren WoodChief Medical OfficerGregory L. ConnChief Scientific OfficerJanetta TrochimiukControllerKey CompetitorsCellectar BiosciencesNASDAQ:CLRBOptiNoseNASDAQ:OPTNSocietal CDMONASDAQ:SCTLCoya TherapeuticsNASDAQ:COYARezoluteNASDAQ:RZLTView All Competitors EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) announced its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE). This page (NASDAQ:EDGE) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.